Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes
Author:
Affiliation:
1. Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Sagamihara 252-0374, Japan
2. Motomiya Diabetes Clinic, Sagamihara 252-0233, Japan
3. Toshiba Rinkan Hospital, Sagamihara 252-0385, Japan
Publisher
Japan Endocrine Society
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Link
https://www.jstage.jst.go.jp/article/endocrj/69/6/69_EJ21-0696/_pdf
Reference26 articles.
1. 1 Del Prato S, Castellino P, Simonson DC, DeFronzo RA (1987) Hyperglucagonemia and insulin-mediated glucose metabolism. J Clin Invest 79: 547–556.
2. 2 Lee PC, Ganguly S, Goh SY (2018) Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev 19: 1630–1641.
3. 3 Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, et al. (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124: 499–508.
4. 4 Okamoto A, Yokokawa H, Sanada H, Naito T (2016) Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. Drugs R D 16: 255–261.
5. 5 Nishimura R, Osonoi T, Kanada S, Jinnouchi H, Sugio K, et al. (2015) Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study. Diabetes Obes Metab 17: 800–804.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems—A Literature Review;International Journal of Molecular Sciences;2024-02-06
2. Glucagon secretion and its association with glycaemic control and ketogenesis during sodium‐glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open‐label, prospective study;Diabetes, Obesity and Metabolism;2024-01-22
3. Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved;Clinical Nutrition;2023-12
4. Robust increase in glucagon secretion after oral protein intake, but not after glucose or lipid intake in Japanese people without diabetes;Journal of Diabetes Investigation;2023-07-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3